CLP, OTCCNLF) shares rose 6% on Wednesday after the company began dosing patients in a new arm of its Phase II melanoma trial, marking a key step in the development of its next-generation cancer immunotherapy. The new cohort, part of the ongoing SCOPE study, will test intradermal delivery and a faster dosing schedule of Scancell's iSCIB1+ Immunobody therapy in combination with checkpoint inhibitors. 